Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Alphamab Oncology ( (HK:9966) ) has shared an update.
Alphamab Oncology has announced its upcoming Annual General Meeting scheduled for June 12, 2025, in Suzhou, China. The meeting will address several key resolutions, including the approval of financial statements and the authorization for directors to repurchase shares and issue additional shares. These resolutions are expected to impact the company’s operational strategies and shareholder value, reflecting its commitment to maintaining a strong market position and enhancing shareholder returns.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a biopharmaceutical company focused on the development and commercialization of innovative cancer therapies. The company operates in the oncology sector, providing products and services aimed at addressing unmet medical needs in cancer treatment.
Average Trading Volume: 5,332,187
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.85B
Learn more about 9966 stock on TipRanks’ Stock Analysis page.